Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 139,921	$ 143,583
Accounts receivable	9,002	845
Prepaid expenses	7,069	4,250
Other current assets	2,318	1,782
Marketable securities	86,012	85,020
Short term investments	79,394	86,890
TOTAL CURRENT ASSETS	323,716	322,370
Property and equipment, net	33,730	30,881
Intangible assets, net	14,938	15,363
Long term investments	110,855	137,487
Right-of-use assets	15,747	16,138
Other assets	265	265
TOTAL ASSETS	499,251	522,504
CURRENT LIABILITIES
Accounts payable	4,827	6,829
Accrued expenses	9,570	5,389
Accrued payroll and benefits	2,753	8,061
Lease liabilities	1,183	1,095
Deferred revenue	6,744	19,291
Other current liabilities	17	16
TOTAL CURRENT LIABILITIES	25,094	40,681
LONG-TERM LIABILITIES
Lease liabilities, net of current portion	19,685	20,044
TOTAL LONG-TERM LIABILITIES	19,685	20,044
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:
Common stock, $0.001 par value; 145,000 shares authorized; 103,194 and 102,376 shares issued and outstanding as of December 31, 2020 and September 30, 2020, respectively	195	195
Additional paid-in capital	978,655	965,410
Accumulated other comprehensive income (loss)	198	18
Accumulated deficit	(524,576)	(503,844)
TOTAL STOCKHOLDERS’ EQUITY	454,472	461,779
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 499,251	$ 522,504